VEGFA and neoplasm: The patients’ tumors were characterized by high VEGF-R2 to Ktrans ratio before treatment, by a lack of tumor size reduction after two weeks’ single dose of bevacizumab and by transient bevacizumab-induced vascular control that was reflected by less profound and less durable reductions in Tie2.